Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study of Neumifil for the prevention and treatment of COVID-19

Trial Profile

A clinical study of Neumifil for the prevention and treatment of COVID-19

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 28 May 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Neumifil (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions
  • Most Recent Events

    • 28 May 2020 New trial record
    • 27 May 2020 According to a Pneumagen media release, the company plans to initiate this study in the first half of 2021.
    • 27 May 2020 According to a Pneumagen media release, the company has received the GBP 4 million euros investment led by Thairm Bio with additional investment from the Scottish Investment Bank for the clinical development of Neumifil for COVID-19 infection.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top